Fig. 1: Viability assessment of the PDX tumor tissue after paclitaxel treatment. | npj Breast Cancer

Fig. 1: Viability assessment of the PDX tumor tissue after paclitaxel treatment.

From: Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay

Fig. 1: Viability assessment of the PDX tumor tissue after paclitaxel treatment.

a Representative images of the EdU (pink) and DAPI (blue) channels for two selected PDX models: HBCx-204 and HBCx-39. b Combined EdU/DAPI results for each model separately relative to the control, with mean and SEM indicated. c EdU/DAPI replication results after paclitaxel treatment of two selected PDX models (HBCx-204 and HBCx-39). Each data point represents the percentage of replicating cells within one microscopic field of view; ten fields of view were analyzed for each of the three biological replicates. d Combined EdU/DAPI results divided in paclitaxel sensitive and resistant models. e Representative images of the TUNEL (green) and DAPI (blue) channels for two selected PDX models: HBCx-4B and HBCx-147. f Combined TUNEL/DAPI results for each model separately relative to the control by subtracting it from the TUNEL levels after treatment. Error bars represent the SEM. g TUNEL/DAPI replication results after treatment with paclitaxel of two selected PDX models (HBCx-4B and HBCx-147). Each data point represents the percentage of replicating cells within one microscopic field of view; ten fields of view were analyzed for each of the three biological replicates.

Back to article page